A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1159/000086317.
Affiliations
- PMID: 16088264
- DOI: 10.1159/000086317
Randomized Controlled Trial
A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine
Eriko Nakatani et al. Psychother Psychosom. 2005.
Abstract
Background: The aim of this study was to confirm and compare the efficacy of fluvoxamine (the only licensed SSRI for treatment for OCD in Japan) and behavior therapy in treating Japanese patients with OCD. In addition, we investigated predictors of these treatments.
Methods: Thirty-one outpatients meeting the DSM-III-R criteria for OCD without any axis I disorder were randomly assigned to one of three treatment conditions: BT (behavior therapy +/- pill placebo), FLV [autogenic training (a psychological placebo for OCD) +/- fluvoxamine] and control group [autogenic training (psychological placebo) +/- pill placebo] for 12 weeks of treatment. The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and the Clinical Global Impression-Improvement Scale (CGI-I) were administered blindly at baseline and week 4, 8 and 12.
Results: Twenty-eight patients completed this study. Patients in the BT and FLV groups showed significantly more improvement than those in the control group in the mean score of total Y-BOCS; moreover, the BT group showed significantly more reduction in total Y-BOCS score at the end of treatment than the FLV group (BT > FLV, p < 0.01). Patients with lower baseline total Y-BOCS, past history of a major depressive episode and absence of cleaning compulsion improved more with fluvoxamine.
Conclusions: We confirmed the effectiveness of behavior therapy and fluvoxamine for Japanese patients with OCD. Behavior therapy improved the condition of OCD patients more than fluvoxamine.
Copyright 2005 S. Karger AG, Basel.
Similar articles
- L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Nematizadeh M, Ghorbanzadeh H, Moghaddam HS, Shalbafan M, Boroon M, Keshavarz-Akhlaghi AA, Akhondzadeh S. Nematizadeh M, et al. Psychiatry Clin Neurosci. 2023 Sep;77(9):478-485. doi: 10.1111/pcn.13565. Epub 2023 May 27. Psychiatry Clin Neurosci. 2023. PMID: 37169515 Clinical Trial. - Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. Askari N, et al. CNS Drugs. 2012 Oct 1;26(10):883-92. doi: 10.2165/11635850-000000000-00000. CNS Drugs. 2012. PMID: 22873680 Clinical Trial. - Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J. Alonso P, et al. J Clin Psychiatry. 2001 Jul;62(7):535-40. doi: 10.4088/jcp.v62n07a06. J Clin Psychiatry. 2001. PMID: 11488364 Clinical Trial. - D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.
Xia J, Du Y, Han J, Liu G, Wang X. Xia J, et al. Drug Des Devel Ther. 2015 Apr 21;9:2101-17. doi: 10.2147/DDDT.S68994. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25960632 Free PMC article. Review. - Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
Figgitt DP, McClellan KJ. Figgitt DP, et al. Drugs. 2000 Oct;60(4):925-54. doi: 10.2165/00003495-200060040-00006. Drugs. 2000. PMID: 11085201 Review.
Cited by
- Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder.
Wen SL, Cheng MH, Cheng MF, Yue JH, Wang H. Wen SL, et al. Behav Brain Funct. 2013 Jul 30;9:31. doi: 10.1186/1744-9081-9-31. Behav Brain Funct. 2013. PMID: 23898909 Free PMC article. Clinical Trial. - Perinatal Obsessive-Compulsive Disorder: Epidemiology, Phenomenology, Etiology, and Treatment.
Hudepohl N, MacLean JV, Osborne LM. Hudepohl N, et al. Curr Psychiatry Rep. 2022 Apr;24(4):229-237. doi: 10.1007/s11920-022-01333-4. Epub 2022 Apr 6. Curr Psychiatry Rep. 2022. PMID: 35384553 Free PMC article. Review. - Novel ensemble method for the prediction of response to fluvoxamine treatment of obsessive-compulsive disorder.
Hasanpour H, Ghavamizadeh Meibodi R, Navi K, Asadi S. Hasanpour H, et al. Neuropsychiatr Dis Treat. 2018 Aug 10;14:2027-2038. doi: 10.2147/NDT.S173388. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 30127613 Free PMC article. - Cognitive Behavioural Therapy for Obsessive-Compulsive Disorder Related to the Fear of Internet Use: A Case Study.
Ishikawa R. Ishikawa R. Cureus. 2024 Sep 30;16(9):e70584. doi: 10.7759/cureus.70584. eCollection 2024 Sep. Cureus. 2024. PMID: 39483930 Free PMC article. - Psychotherapy and medication management strategies for obsessive-compulsive disorder.
Walsh KH, McDougle CJ. Walsh KH, et al. Neuropsychiatr Dis Treat. 2011;7:485-94. doi: 10.2147/NDT.S13205. Epub 2011 Aug 23. Neuropsychiatr Dis Treat. 2011. PMID: 21931490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous